Pricing Log in Create free account
Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

CAI Healthcare Biotechnology

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue
+27.0%
EPS
−40.3%
Free cash flow
−140.2%
Total debt
+4.46%

Quarter to September 2026, against a year earlier

24.58 1.45 −5.57%
Market cap
$7.4B
P/E
77.7×
Fwd P/E
254×
Dividend yield
—
F-score
n/a
Altman Z
3.55
Beneish M
−2.71
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Caris Life Sciences,�Inc. (CAI) SEC filings, changes and red flags

Red flags

  • Material weakness

    Caris Life Sciences,�Inc.’s 10-Q reports a material weakness in internal control over financial reporting

    Other than the foregoing actions to remediate our material weakness, there was no change in our internal control over financial reporting identified during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

    10-Q filed · The filing · sec.gov

  • Receivables outpacing revenue

    Receivables grew 399.4% while revenue grew 27.0% year over year

    10-Q filed · The filing · sec.gov

  • Inventory outpacing revenue

    Inventory grew 204.8% while revenue grew 45.4% year over year

    10-Q filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 1 added · 19 removed · 38 modified
P2I1A: no changes 		Material weakness Receivables outpacing revenue
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 14, 2026 7.01 Regulation FD disclosure
10-Q Jun 30, 2026 P1I2: 20 added · 11 removed · 42 modified
P2I1A: no changes 		Inventory outpacing revenue
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 4, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 1, 2026 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation
10-K Dec 31, 2025 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 26, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 30, 2025 3.03 Material modification of shareholders' rights; 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.